Recently Approved

December 2006
Pharmaceutical Representative;Dec2006, Vol. 36 Issue 12, p14
The article reports on the approval of drugs by the U.S. Food and Drug Administration. The agency has approved the new indication for Avastin® from Genentech Inc. as a treatment for non-small cell lung cancer. Brovana™ from Sepracor Inc. has been approved for long-term maintenance treatment in patients with chronic obstructive pulmonary disease. Pylera™ from Axcan Pharma Inc. has been approved for the treatment of patients with Helicobacter pylori infection.


Related Articles

  • Pipeline.  // Medical Marketing & Media;Nov2006, Vol. 41 Issue 11, p10 

    The article reports developments related to drug approval issued by the U.S. Food and Drug Administration. Merck and Co. Inc. has won an approval for Zolinza, which is indicated for cutaneous manifestations in patients with cutaneous T-cell lymphoma. GlaxoSmithKline PLC was granted approval for...

  • New molecular entities.  // Formulary;Nov2006, Vol. 41 Issue 11, p555 

    The article presents information on the recently developed drugs by various pharmaceutical companies in the United States. Theses drugs are approved by the U.S. Food and Drug Administration (FDA) for their therapeutic use. Sepracor Inc. has developed Brovana in the group of arformoterol. Brovana...

  • Ultrase NDA preserves availability on regulated market. Buono, Drew // Drug Store News;5/19/2008, Vol. 30 Issue 6, p22 

    The article reports on the ban of pancreatic enzyme products by the U.S. Food and Drug Administration (FDA). Manufacturers of the said drugs are mandated to submit a new drug application (NDA) or an investigation drug application (IDA), and those who failed to do so will be banned from selling...

  • Axcan Pharma Rejected for Ulcer Drug Combo. Mirasol, Feliza // Chemical Market Reporter;10/13/2003, Vol. 264 Issue 12, p10 

    Reports on the Food and Drug Administration's disapproval of a drug combination application for ulcer treatment from pharmaceutical company Axcan Pharma Inc. in the U.S. Name of the drug; Formulation and mechanism of action; pharmacokinetics of the product.

  • Decisions Update.  // PharmaWatch: Biotechnology;Jun2005, Vol. 4 Issue 6, p12 

    The article presents several updates related to new drug applications addressed to the U.S. Food and Drug Administration. Genentech Inc.'s new drug application to start a phase 1 clinical trial of a Curis Inc. co-developed drug for basal cell carcinoma has been approved. Medarex Inc. was granted...

  • Pipeline.  // Medical Marketing & Media;Apr2004, Vol. 39 Issue 4, p10 

    Reports on developments concerning the pharmaceutical industry in the U.S., compiled as of April 2004. U.S. Food and Drug Administration's (FDA) approval of Genentech Inc.'s Avastin in combination with venous 5-Fluorouracil-based chemotherapy; FDA's approval of Daiichi Pharmaceutical Corp.'s...

  • Epilepsy Update.  // PharmaWatch: CNS;Jun2010, Vol. 9 Issue 6, p11 

    The article offers updates on issue related to pharmaceutical industry. Eisai Co. Ltd. plans to commence a clinical trial in Japan with the antiepileptic agent rufinamide in patients with a rare disorder known as lennox-gastaut syndrome. Sepracor Inc. receives a complete response letter from the...

  • First angiogenesis inhibitor OK'd.  // Drug Topics;3/8/2004, Vol. 148 Issue 5, p8 

    Reports on the U.S. Food and Drug Administration's approval of bevacizumab manufactured by Genentech Inc. to be used in combination with IV 5-fluororouracil-based chemotherapy as a treatment for patients with previously untreated metastatic colorectal carcinoma.

  • Decisions Update.  // PharmaWatch: Biotechnology;Jun2009, Vol. 8 Issue 6, p14 

    The article reports developments in the pharmaceutical industry in the U.S. from April 15-May 14, 2009. An accelerated approval of Avastin for people with glioblastoma was reported by Genentech Inc. The orphan drug status for Oncophage for the treatment of glioma was granted to Antigenics. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics